X
[{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Ramelteon Tablets","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Three Additional Strengths Of Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Dicyclomine Hydrochloride Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Fluphenazine Hydrochloride Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules, USP","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Pitavastatin Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Upsher-Smith Laboratories, Inc
Filters
Companies By Therapeutic Area
Details:
Through the acquisition, Bora gains Upsher-Smith’s product portfolio, including Amantadine hydrochloride, indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Lead Product(s):
Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases
Product Name: Amantadine HCl-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Bora Pharmaceuticals
Deal Size: $210.0 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
January 18, 2024
Details:
Pitavastatin tablet is a HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in Adult patients with primary hyperlipidemia or mixed dyslipidemia.
Lead Product(s):
Pitavastatin
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Livalo-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 06, 2023
Details:
Mesalamine, also known as 5-aminosalicylic acid extended-release capsule is a small molecule, which is indicated for the maintenance of remission of ulcerative colitis in adults.
Lead Product(s):
Mesalazine
Therapeutic Area: Gastroenterology
Product Name: Apriso-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 21, 2023
Details:
Isotretinoin capsule inhibits sebaceous gland function and keratinization at pharmacologic doses. It is being indicated for the treatment of severe recalcitrant nodular acne.
Lead Product(s):
Isotretinoin
Therapeutic Area: Dermatology
Product Name: Accutane-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 24, 2023
Details:
Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.
Lead Product(s):
Sumatriptan
Therapeutic Area: Neurology
Product Name: Zembrace SymTouch
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million
Upfront Cash: $22.0 million
Deal Type: Acquisition
July 03, 2023
Details:
The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.
Lead Product(s):
Sumatriptan
Therapeutic Area: Neurology
Product Name: Zembrace SymTouch
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million
Upfront Cash: $22.0 million
Deal Type: Acquisition
June 26, 2023
Details:
Fluphenazine hydrochloride Tablets are a generic version of the brand product, Prolixin. Company has launched Fluphenazine Hydrochloride Tablets, USP in four strengths, 1 mg, 2.5 mg, 5 mg, and 10 mg.
Lead Product(s):
Fluphenazine
Therapeutic Area: Psychiatry/Psychology
Product Name: Prolixin-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 03, 2023
Details:
Dicyclomine hydrochloride is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.
Lead Product(s):
Dicyclomine Hydrochloride
Therapeutic Area: Gastroenterology
Product Name: Dicyclomine Hydrochloride-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 06, 2023
Details:
Upsher-Smith’s product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules in 10 mg, 20 mg, 30 mg and 40 mg strengths used to treat severe cystic acne.
Lead Product(s):
Isotretinoin
Therapeutic Area: Dermatology
Product Name: Isotretinoin-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Mayne Pharma
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2021
Details:
Upsher-Smith’s product is AB-rated to the branded product, Tegretol® XR (carbamazepine extended-release tablets). The carbamazepine extended-release tablet market had U.S. sales of approximately $120 million for the 12 months ending June 2021 according to IQVIA.
Lead Product(s):
Carbamazepine
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 16, 2021